Revenue segments as reported by the company.

Clearing and transaction fees

Market data and information services

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Compensation and benefits  

Technology

Professional fees and outside services

Amortization of purchased intangibles

Depreciation and amortization

Licensing and other fee agreements

Other expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

CME Group

CME Group, Inc. operates a derivatives marketplace, which offers a range of futures and options products for risk management. Its exchanges offer a range of global benchmark products across all major asset classes based on interest rates, equity indexes, foreign exchange (FX), energy, agricultural commodities and metals. It offers futures and options on futures trading across asset classes through the CME Globex platform, fixed income trading via BrokerTec and FX trading on the EBS platform. In addition, it also operates CME Clearing, a central counterparty clearing provider. The company was founded in 1898 and is headquartered in Chicago, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

CME Group achieves record-breaking 2022 performance amidst market challenges

CME Group's 2022 performance was exceptional, marked by record volumes, revenue growth, and successful transitions. The company's focus on innovation, strategic positioning in energy and cryptocurrency markets, and pricing adjustments have driven positive outcomes. Challenges in margins and market uncertainties require careful navigation.

CME Group posts record Q1 earnings, eyes growth in SOFR

CME Group delivered a strong performance in Q1 2023, achieving record revenue and profitability driven by growth in interest rate and options trading.
The company's strategic focus on risk management, shareholder value creation, and market competitiveness positions it well for future growth and revenue generation.
While facing challenges in a competitive market environment, CME Group has opportunities to capitalize on the demand for SOFR products and options trading.
Optimism surrounding the company's future growth potential, coupled with effective expense management and revenue diversification, underpin its resilience and strategic outlook.

CME Group excels in Q2 with record revenue and strategic focus

CME Group's Q2 earnings call showcased strong financial performance, driven by growth across asset classes and a focus on customer-centric strategies. The company's emphasis on innovation, regulatory compliance, and market leadership positions it well for future growth.

CME Group reports strong Q3 earnings, eyes growth amid challenges

CME Group's Q3 2023 earnings call highlighted robust financial performance, operational efficiency, and strategic positioning. Despite facing regulatory challenges and cost management concerns, the company remains confident in its offerings and growth prospects. Opportunities for expansion through innovation and capitalizing on market trends were key discussion points.

CME Group achieves record 2023 results amidst global uncertainties

CME Group's record-breaking performance in 2023 underscores its market leadership and financial strength, with revenue growth, margin expansion, and strong product demand driving positive results.
While facing challenges from global uncertainties and market dynamics, the company's strategic focus on innovation, risk management, and efficiency positions it well to capitalize on opportunities in evolving markets.
By introducing new products, expanding partnerships, and navigating changing market conditions adeptly, CME Group demonstrates resilience and adaptability, paving the way for continued growth and success in the financial industry.
Overall, CME Group's strategic initiatives, financial performance, and market positioning reflect a company poised for sustained success, leveraging opportunities and strengths to overcome challenges and drive future growth.

CME Group achieves record earnings in Q1 2024, eyes growth

CME Group delivered a strong performance in Q1 2024, setting records in revenue and earnings.
The company faces challenges in managing expenses amid growth initiatives and competitive dynamics.
However, CME's strengths in market leadership, network infrastructure, and regulatory alignment position it well for future opportunities.
By capitalizing on data services and revenue growth avenues, CME can continue its upward trajectory in the market.

CME Group achieves record Q3 performance amidst regulatory challenges

CME Group's Q3 performance was exceptional, marked by record volumes and financial metrics. Despite challenges in regulatory compliance and competition, the company is well-positioned for growth through strategic opportunities in interest rate products and retail expansion.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Brookfield Asset Management

Synchrony Financial

It's a great time to buy financial stocks, and these three are long-term winners.

3 Top Financial Stocks to Buy in January

CME Group (NASDAQ: CME) operates futures and derivatives exchanges including the Chicago Mercantile Exchange, the New York Mercantile Exchange and the Chicago Board of Trade, as well as the Dow Jones Index Services.

How Has CME Group’s Acquisition Of NEX Changed Its Revenue Composition?

Alnylam Pharmaceuticals

CRISPR Therapeutics

iShares Nasdaq Biotechnology ETF

NVIDIA

In 5 years, you be selling your gold and buying more companies leading the century of biology.

Trade of the 2020's: Sell Gold, Buy Biotech

When investors do their stock picking by following gurus or hedge fund managers, it is important for them to keep track of when these parties are actually exiting their investments.

Does the Insider Selling Imply That It Is Time to Exit CME Group?

Intercontinental Exchange

CME And ICE - Buy Any Dips

CME Group Inc. (CME) CEO Terrence Duffy on Q3 2019 Results - Earnings Call Transcript

CME Group's (CME) third-quarter 2019 results reflect solid trading volumes.

CME Group (CME) Q3 Earnings and Revenues Top Estimates

CME Group has been struggling lately, but the selling pressure may be coming to an end soon.

CME Group Sees Hammer Chart Pattern: Time to Buy?

Peloton

Yes, the printed word can still have an effect on stocks, even in the 21st century.

Why the Market Punished These 2 Stocks on Monday

Falling share prices are a boon for these companies -- and their investors.

2 Top Stocks to Buy During a Market Downturn

Does CME Group (CME) have what it takes to be a top stock pick for momentum investors? Let's find out.

Here's Why CME Group (CME) is a Great Momentum Stock to Buy

CME Group's (CME) Q3 volumes of 20.2 million contracts reflect an increase of 30% year over year.

CME Group Q3 Volumes Solid, September ADV Increases Y/Y

CME Group (CME) is poised to grow given its strategic growth initiatives and solid capital position.

CME Group's (CME) Acquisitions and Investments Drive Growth

CME Group (CME) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

How CME Group (CME) Stock Stands Out in a Strong Industry

Strong revenue gains and better-than-expected profits helped to drive the exchange-titan's shares sharply higher.

Why CME Group Stock Rose 12% in August

Sr MD COO of Cme Group Inc (30-Year Financial, Insider Trades) Julie Holzrichter (insider trades) sold 3,436 shares of CME on 09/03/2019 at an average price of $216.07 a share.

Cme Group Inc (CME) Sr MD COO Julie Holzrichter Sold $742,417 of Shares

CME Group's (CME) August volumes of 24.3 million contracts reflect an increase of 53% year over year.  Treasury futures and Metals marks record volumes.

CME Group (CME) Records Second-Highest Monthly ADV in August

CME Group Has Been The Stock That Keeps On Giving

Block

These outstanding businesses are well-positioned to profit from the rising popularity of bitcoin and other cryptocurrencies.

2 Top Blockchain Stocks to Buy Now

Strong international growth and acquisition-fueled gains are driving the exchange giant's expansion.

CME Group Revenue Rises 20%

CME Group Inc. (CME) CEO Terrence Duffy on Q2 2019 Results - Earnings Call Transcript

AvalonBay Communities

Howard Hughes

Monolithic Power Systems

Microsoft

NIKE

Progressive

The Parnassus Fund disclosed this week it established seven new positions during the second quarter: Microsoft Corp.

Parnassus Fund Buys 7 Stocks in 2nd Quarter

Newmont Mining

Northrop Grumman

Starbucks

Thermo Fisher Scientific

Fed's rate cut will not only make cheaper funds available to businesses and stock market investors, but also U.S. dollar less expensive in the international market.

Can Fed Put Counter Potential Negative Q2 Earnings? 5 Picks

Sr MD CFO of Cme Group Inc (NASDAQ:CME) John W. Pietrowicz (insider trades) sold 2,500 shares of CME on 07/09/2019 at an average price of $201.3 a share.

Cme Group Inc (CME) Sr MD CFO John W. Pietrowicz Sold $503,250 of Shares

CME Group's (CME) solid second quarter volumes reflects record quarterly ADV in Agricultural Commodities, Interest Rate options, Agricultural options and Metals options.

News for CME Group Stock (CME)